Abstract

Pseudomonas aeruginosa (strain 48-1997A) producing Sao Paulo metallo-beta-lactamase (MBL)-1 (SPM-1) was described for the first time in 1997 and came from a 4-year-old leukemic girl in Sao Paulo, Brazil (15). Since then, SPM-1-producing P. aeruginosa has become endemic in Brazilian hospitals, being recurrently associated with outbreaks of nosocomial infection (8, 11, 12). More recently, the first reports of the MBL SPM-1 were described in Europe (14) and western Asia (GenBank accession no. {type:entrez-nucleotide,attrs:{text:HM370523.1,term_id:307949947,term_text:HM370523.1}}HM370523.1), denoting the potential for SPM-1 to become endemic worldwide (6). Unfortunately, carbapenem-resistant P. aeruginosa isolates carrying the SPM-1 enzyme have exhibited additional resistance to aminoglycosides, which has been mediated by a novel 16S rRNA methylase defined as RmtD (3), rendering ineffective a potent double-coverage regimen of a carbapenem plus an aminoglycoside and contributing to the emergence of panresistant phenotypes (3, 4). In this letter, we report the first environmentally isolated Pseudomonas aeruginosa carrying the blaSPM-1 and rmtD1 genes, providing additional data on the epidemiology of these genetic determinants of resistance. In August of 2010, during a surveillance study established to monitor the occurrence of antimicrobial resistance in Gram-negative bacteria from urban rivers in southeastern Brazil, a panresistant P. aeruginosa isolate (TIES-04900) was recovered from the Tiete River. Tiete is one of the main rivers of the region, which runs across Sao Paulo state from east to west for about 1,100 km. The water sample was collected from a dam located downstream of many important cities, including Sao Paulo, the largest and most populous metropolitan area in Brazil. P. aeruginosa strain TIES-04900 was resistant to imipenem, meropenem, ertapenem, ceftazidime, cefotaxime, cefepime, piperacillin-tazobactam, amikacin, tobramycin, gentamicin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole; remaining susceptible only to aztreonam and polymyxin B (Table 1). MBL production was confirmed by using an MBL Etest strip. Based on the antimicrobial susceptibility pattern and genetic backgrounds of multidrug-resistant P. aeruginosa strains reported from Brazil (4, 8), antibiotic resistance genes were studied by PCR and sequencing, confirming the presence of the blaSPM-1, blaOXA-56, rmtD1, aacA4, aadA7, sul1, and dhfr genes (GenBank accession numbers {type:entrez-nucleotide,attrs:{text:HQ876773,term_id:323099809,term_text:HQ876773}}HQ876773 to {type:entrez-nucleotide,attrs:{text:HQ876777,term_id:323099817,term_text:HQ876777}}HQ876777). This resistance genotype has been previously reported in clinical isolates of P. aeruginosa (3) and most likely has contributed to the endemicity of this panresistant phenotype in Brazilian hospitals (3, 4, 6, 8, 11, 12). In fact, enterobacterial repetitive intergenic consensus-PCR fingerprint analysis (Dice similarity coefficient and unweighted-pair group method using average linkages clustering), undertaken to ascertain the relatedness of TIES-04900 to clinical SPM-1- and RmtD-1-positive P. aeruginosa isolates (3, 15), showed that environmental P. aeruginosa TIES-04900 was clonally related to human P. aeruginosa strains PA0905 (95.2% similarity) and 48-1997A (90% similarity), previously identified in Sao Paulo (3, 15). Table 1. MICs of antibiotics for environmental Pseudomonas aeruginosa strain TIES-04900 carrying the blaSPM-1, blaOXA-56, rmtD1, aacA4, aadA7, sul1, and dhfr genesa In summary, we report the presence of SPM-1- and RmtD-1-coproducing P. aeruginosa in an urban river, showing that strains harboring the blaSPM-1 and rmtD1 genes seem not to be restricted to the hospital setting, a fact that emphasizes the importance of surveying environmental strains that might act as a source and/or reservoir of resistance genes with clinical relevance (1, 5, 7, 13) and have the potential for dissemination in communities through river environments (1, 10).

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.